ly 293558 has been researched along with atropine in 2 studies
| Studies (ly 293558) | Trials (ly 293558) | Recent Studies (post-2010) (ly 293558) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
|---|---|---|---|---|---|
| 103 | 4 | 18 | 26,711 | 1,259 | 1,697 |
| Protein | Taxonomy | ly 293558 (IC50) | atropine (IC50) |
|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Green, CE; Qashu, F; Swezey, R; Yang, C | 1 |
| Almeida-Suhett, CP; Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Miller, SL; Prager, EM | 1 |
2 other study(ies) available for ly 293558 and atropine
| Article | Year |
|---|---|
Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
Topics: Animals; Anticonvulsants; Antidotes; Atropine; Brain; Cholinesterase Inhibitors; Electroencephalography; Fluoresceins; Fluorescent Dyes; Injections, Intramuscular; Isoquinolines; Male; Muscarinic Antagonists; Nerve Degeneration; Oximes; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles; Tissue Fixation | 2013 |
A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.
Topics: Acetylcholinesterase; Animals; Anticonvulsants; Atropine; Chemical Warfare Agents; Cholinesterase Inhibitors; Disease Models, Animal; Hippocampus; Isoquinolines; Male; Nerve Degeneration; Oximes; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Kainic Acid; Seizures; Soman; Status Epilepticus; Tetrazoles | 2015 |